STOCK TITAN

Amneal Pharmaceuticals Inc - AMRX STOCK NEWS

Welcome to our dedicated news page for Amneal Pharmaceuticals (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amneal Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amneal Pharmaceuticals's position in the market.

Rhea-AI Summary
Amneal Pharmaceuticals adds two denosumab biosimilars to its pipeline, expanding its partnership with mAbxience. The biosimilars reference Prolia® and XGEVA®, and are indicated for the treatment of bone metastasis and prevention of bone pain and fractures. Amneal aims to be a top player in the U.S. biosimilar space and sees biosimilars as the next wave of affordable medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
none
-
Rhea-AI Summary
Amneal Pharmaceuticals to release Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
conferences earnings
-
Rhea-AI Summary
Amneal Pharmaceuticals receives FDA approval for calcium gluconate injection currently on shortage list
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Amneal Pharmaceuticals receives first product approval in China, expects international expansion to drive long-term growth
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
none
-
Rhea-AI Summary
Amneal Pharmaceuticals receives FDA approval for generic version of ADHD medication Vyvanse® currently on shortage list
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
-
Rhea-AI Summary
Senior members of the U.S. Government visit Amneal's manufacturing site in India
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
Rhea-AI Summary
Amneal Pharmaceuticals to participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
conferences
-
Rhea-AI Summary
IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimized IR CD/LD, with fewer daily doses
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
-
Rhea-AI Summary
Amneal Pharmaceuticals reports Q2 2023 net revenue of $599 million, GAAP net income of $12 million, and diluted EPS of $0.08. Adjusted net income of $57 million, adjusted EBITDA of $146 million, and adjusted diluted EPS of $0.19. Raising 2023 full year guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.32%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
Amneal Pharmaceuticals Inc

NYSE:AMRX

AMRX Rankings

AMRX Stock Data

1.68B
123.43M
59.78%
29.02%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bridgewater

About AMRX

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.